Bio-Rad enhances multiplex flow cytometry with three new StarBright UltraViolet Dyes
The StarBright UltraViolet 510, StarBright UltraViolet 665, and StarBright UltraViolet 795 Dyes Offer Exceptional Brightness with Narrow Excitation and Emission Profiles to Support Multiplex Panels.
Avacta announces AffyXell joint venture milestone and increased equity stake
Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics, a joint venture between Avacta and Daewoong Pharmaceutical in South Korea.
Bio-Rad introduces anti-cemiplimab antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, introduces a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1). These ready-made antibodies are suitable for developing selective and sensitive assays for bioanalysis and drug…
AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center
Cambridge and Wetherby: Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that AffyXell Therapeutics, a joint venture between Avacta and Daewoong Pharmaceutical, has entered into a collaboration agreement with Biocytogen, a Chinese company specializing in developing new…
Axol Bioscience raises £3.2 million GBP
Cambridge, UK: Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, announces that it has raised £3.2 million GBP (circa $4.2 million USD) in the extension of its previous funding round, bringing the total raised to £7 million GBP (circa $9.2 million USD). The round was led by existing investors…
Insightful Science bolsters executive team with senior sales and marketing expertise to accelerate growth Initiatives
San Diego, CA: Insightful Science, the global leader in R&D scientific software that connects science, data, and decision-making, today announced the appointments of Marta DeBellis as Chief Marketing Officer (CMO), and Stephanie Furfaro as Chief Revenue Officer (CRO). The appointments further strengthen the executive team as the Company continues to grow exponentially and scales the…
Cell Guidance Systems and Manchester BIOGEL collaborate to launch PODS-PeptiGels for 3D cell culture
Cell Guidance Systems Ltd, a specialist in the control, manipulation, and monitoring of cells, both in vitro and in vivo, and Manchester BIOGEL, a biotechnology company specialising in the design and manufacture of 3D synthetic peptide hydrogels, announces a collaboration to launch PODS®-PeptiGels®.
Evonetix granted patent for technology enabling thermally-controlled DNA synthesis
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, announces it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips.
Arrayjet introduces Mercury range of next-generation microarray printers
Edinburgh, Scotland: Arrayjet, a leading provider of inkjet liquid-handling solutions, today introduced Mercury, a new core range of five instruments for ultra-low-volume liquid dispensing. The new print dispensers offer radically improved functionality and reliability, with further enhanced speed and precision.
Fujifilm completes acquisition of Shenandoah Biotechnology
TOKYO: FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading…
Fujifilm to acquire Shenandoah Biotechnology, leading manufacturer of recombinant proteins
The acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies.
Closed Loop Medicine announces completion of Precision Medicine Clinical Trial for patients with high blood pressure
Cambridge and London: Closed Loop Medicine Ltd, a leader in the development of single prescription drug plus digital therapy (DTx) combination products to enable precision dosing and care, announces that the last patient has completed participation in a clinical trial investigating the Company’s integrated precision care product solution for patients with hypertension.
Avacta appoints Dr Christina Coughlin as Non-Executive Director
Cambridge and Wetherby: Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.
ELRIG UK establishes Scientific Advisory Board
York, UK: The European Laboratory Research & Innovation Group (ELRIG) UK announces the formation of its Scientific Advisory Board (SAB) with the appointment of senior drug discovery experts: Dr Chas Bountra OBE, Dr Richard Eglen, Steve Rees OBE, Dr Cathy Tralau-Stewart, and Dr Ian Waddell.
Flow Eighteen38 receives €5 million EUR (c.$5.58 million USD) to expand production and biophysical capabilities
Porto, Portugal, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, today announced a €5 million EUR (c.$5.58 million USD) investment into its protein production and biophysical characterization capabilities and services from its parent company, FairJourney Biologics S.A. (FJB), leaders in the discovery…
Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies
Oxford, United Kingdom, Orbit Discovery (Orbit), a ground-breaking peptide discovery company, announces the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
Gyros Protein Technologies introduces PurePep Sonata+ peptide synthesizer
Uppsala, Sweden: Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of PurePep® Sonata®+, a mid-pilot scale peptide synthesizer. The new system is an upgraded version of the Company’s previous model, Sonata® XT, known for its reliability and robustness, to further strengthen the…
Evonetix demonstrates novel enzymatic DNA synthesis method
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry.
Optibrium adds augmented intelligence for compound design to its StarDrop small molecule drug discovery software
Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis.
Dotmatics releases Platform 22.1 - delivering new capabilities to streamline lab workflows
Latest Platform delivers new capabilities to streamline lab workflows and support customers’ data-informed decision making.
Centauri Therapeutics closes £24 million GBP Series A investment round
Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announces the close of its £24 million GBP (c. 32 million USD) Series A investment round.
OxDX raises £2.6M pre-seed funding to develop AI powered rapid diagnostic technology
Technology aims to improve speed, cost and accuracy of infectious disease diagnostics. The funding will be used to expand team and further validate technology.
Bio-Rad introduces anti-daratumumab antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.
Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer
Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic.
Phico Therapeutics establishes Scientific Advisory Board
SAB will provide scientific oversight and strategic advice to support the progression Phico’s engineered phage antibacterial therapy, SASPject, through clinical trials.